Recent Updates
Recently added Catalysts
SIGA Positive Sentiment Score: 70/100

SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results

Key Takeaway: SIGA Technologies, Inc. will host a business update call on November 6, 2025, at 4:30 PM ET to discuss its third-quarter results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. Participants can join via phone or a live webcast, with a replay available afterward. SIGA is known for its antiviral product TPOXX, aimed at treating smallpox and other orthopoxvirus infections.

Market Sentiment Analysis

POSITIVE FACTORS

  • SIGA is actively engaging with investors through a business update call.
  • The company is focused on innovative medicines for infectious diseases.
  • Management will provide insights on third-quarter results, indicating transparency.

Full Press Release Details

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 6, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
A live webcast of the call will also be available on the Company's website athttp://www.siga.comin the Investor Relations section of the site, or byclicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1141989. The archived webcast will be available in the Investor Relations section of theCompany's website.
About SIGASIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visitwww.siga.com.

Contact:Suzanne Harnettsharnett@siga.com

Frequently Asked Questions

When is SIGA's business update call scheduled?

The business update call is scheduled for November 6, 2025, at 4:30 PM ET.

Who will participate in the SIGA update call?

Diem Nguyen, CEO, and Daniel Luckshire, CFO, will participate in the call.

How can I access the SIGA business update call?

You can access the call by phone or through a live webcast on SIGA's website.

Is there a replay available for the SIGA call?

Yes, a replay will be available for two weeks after the call.

Last updated: Oct 30, 2025